

LEARNING GUIDE

PRESERVING BRAIN HEALTH: GOING BEYOND FOCAL INFLAMMATION

PART 3: ADVANCED IMAGING TECHNIQUES IN ROUTINE CLINICAL PRACTICE

AUBAGIO® (teriflunomide) and LEMTRADA®▼ (alemtuzumab) prescribing information and adverse event reporting can be found at the end of this document.



**ACADEMY
OF KNOWLEDGE**
MS SCIENTIFIC EXCHANGE FORUM

KEY LEARNINGS

- Cortical lesions have been associated with higher risk of secondary progressive MS (SPMS) and shorter latency to SPMS¹
- Grey matter atrophy is correlated with the stage of MS severity²
- A combined model of ventricular and lesion volume change predicted 10-year EDSS in all MS patients ($R^2=0.74$) and relapse-onset MS patients ($R^2=0.72$)³
- Magnetisation transfer ratio (MTR) reduction in MS is correlated with demyelination and axonal loss⁴
- Diffusion tensor imaging (DTI) utilises information contained in the orientation and magnitude of water diffusion in tissue to provide insight into the microstructural integrity of underlying tissue⁵, and in one study predicted MS diagnosis with a sensitivity of 87.0% (95% CI, 66.4–97.1) and a specificity of 91.7% (95% CI, 73.0–98.7)⁶

1. Scalfari A. et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. *Neurology* 2018;90:e2107-e2118.

2. Fisher E et al. Grey matter atrophy in multiple sclerosis: a longitudinal study. *Ann Neurol* 2008;64:255-65.

3. Popescu V et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2013;84:1082-91.

4. Button T et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. *Mult Scler* 2013;19:241-4.

5. Oh J et al. Multiparametric MRI correlates of sensorimotor function in the spinal cord of multiple sclerosis. *Mult Scler* 2013;19:427-35.

6. Hesseltine SM et al. Diffusion Tensor Imaging in Multiple Sclerosis: Assessment of Regional Differences in the Axial Plane within Normal-Appearing Cervical Spinal Cord. *Am J Neuroradiol* 2006;27:1189-93.

REFLECTIVE LEARNING QUESTIONS

1. What is the process that you follow in your clinics to visualise and understand the role of chronic smouldering inflammation in your patients' MS pathology? How can you apply this to the management of your patients?

2. How do you currently measure brain volume in clinical practice, and why is there a need for new techniques?

3. How can methods such as MTR and DTI be effectively integrated into clinical use rather than being limited to research studies?

FURTHER READING

1. Absinta M et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. *J Clin Invest* 2016;126(7):2597-609.
2. Elliot C et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. *Brain* 2019;142:2787-99.
3. Absinta M et al. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. *JAMA Neurol* 2019;76(12):1474-83.
4. Absinta M et al. Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. *Am J Neuroradiol* 2018;39:1233-38.
5. Kaunzner UW et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. *Brain* 2019;142:133-45.
6. Kuhlmann T et al. An updated histological classification system for multiple sclerosis lesions. *Acta Neuropathol* 2017;133(1):13-24.
7. Absinta M et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. *Nat Rev Neurol* 2016;12(6):358-68.
8. Gillen et al. Significance and In Vivo Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions. *Front Neurol*, 2018;9:255.
9. Haider L et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. *J Neurol Neurosurg Psychiatry* 2014;85(12):1386-95.
10. Choi SR et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. *Brain* 2012;135(Pt 10):2925-37.
11. Kutzelnigg A et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain* 2005;128(Pt 11):2705-12.
12. Howell OW et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. *Brain* 2011;134(Pt 9):2755-71.
13. Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? *Ann Rev Neurosci* 2008;31:247-49.
14. Filippi M et al. Ultra-high-field MR imaging in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2014;85(1):60-6.
15. Kober T et al. MP2RAGE multiple sclerosis magnetic resonance imaging at 3 T. *Inv Radiol* 2012;47(6):346-52.
16. Scalfari A et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. *Neurology* 2018;90:e2107-e2118.
17. Zivadinov R et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. *Exp Rev Neurother* 2016;16:777-93.
18. Henry RG et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. *J Neurol Neurosurg Psychiatry* 2008;79:1236-44.
19. Tao G et al. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. *J Neurol Sci* 2009;282:39-46.
20. Zivadinov R et al. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. *Mult Scler* 2016;22:1709-18.
21. Sicotte NL et al. Regional hippocampal atrophy in multiple sclerosis. *Brain* 2008;131:1134-41.
22. Kiy G et al. Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. *Mult Scler* 2011;17:1088-97.
23. Amato MP et al. Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. *Neurology* 2013;80:1728-33.
24. Fisher E et al. Grey matter atrophy in multiple sclerosis: a longitudinal study. *Ann Neurol* 2008;64:255-65.
25. Lukas C et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2010;81:1351-6.
26. Popescu V et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2013;84:1082-91.
27. Pagani E et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. *Am J Neuroradiol* 2005;26:341-6.
28. De Stefano N et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2016;87:93-99.
29. Sicotte NL. Magnetic resonance imaging in multiple sclerosis: the role of conventional imaging. *Neurol Clin* 2011;29:343-57.
30. Sahraian MA, Eshaghi A. Role of MRI in diagnosis and treatment of multiple sclerosis. *Clin Neurol Neurosurg* 2010;112:609-15.
31. National MS Society. Magnetic resonance imaging (MRI). Available at <http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/diagnosing-ms/magnetic-resonance-imaging-mri/index.aspx> accessed 28 April 2021.
32. Honce JM. Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. *Mult Scler Int* 2013;2013:627870.
33. Button T et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. *Mult Scler* 2013;19:241-4.
34. Schmierer K et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. *J Magn Reson Imaging* 2007;26:41-51.
35. Bakshi R et al. Imaging of multiple sclerosis: Role in neurotherapeutics. *NeuroRx* 2005;2:277-303.
36. Van den Elskamp IJ et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. *Mult Scler* 2010;16:660-9.
37. Hesseltine SM et al. Diffusion Tensor Imaging in Multiple Sclerosis: Assessment of Regional Differences in the Axial Plane within Normal-Appearing Cervical Spinal Cord. *Am J Neuroradiol* 2006;27:1189-93.
38. Oh J et al. Multiparametric MRI correlates of sensorimotor function in the spinal cord of multiple sclerosis. *Mult Scler* 2013;19:427-35.
39. Oh J et al. Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. *Neurology* 2013;80:540-7.
40. Mainiero C et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. *Neurology* 2009;73:941-8.
41. Inglese M, Bester M. Diffusion imaging in multiple sclerosis: research and clinical implications. *NMR Biomed* 2010;23:865-72.
42. Kolind S et al. Myelin water imaging reflects clinical variability in multiple sclerosis. *Neuroimage* 2012;60:263-70.

Certificate

This certifies that you have completed a 35 minute module
'Preserving Brain Health: Going Beyond Focal Inflammation
Part 3: Advanced Imaging Techniques in Routine Clinical Practice'

The CPD Certification Service have certified this module.



AUBAGIO® PRESCRIBING INFORMATION – GB

Prescribing Information: AUBAGIO® 14 mg (teriflunomide) film-coated tablets

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each film-coated tablet contains 14 mg of teriflunomide. **Indication:** AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS). **Dosage and administration:** The treatment should be initiated and supervised by a physician experienced in the management of MS. In adults, the recommended dose of teriflunomide is 14 mg once daily. In paediatric patients (10 years of age and above), the recommended dose is 14mg once daily with body weight >40 kg. AUBAGIO should be taken orally and swallowed whole with some water. AUBAGIO can be taken with or without food.

Elderly (≥65 years): AUBAGIO should be used with caution due to insufficient data on safety and efficacy. **Renal impairment:** No dose adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis. **Hepatic impairment:** No dose adjustment is necessary for patients with mild and moderate hepatic impairment. **Paediatric:** The safety and efficacy in children aged below 10 years have not been established. No data are available.

Contraindications: Hypersensitivity to the active ingredient or excipients. Patients with severe hepatic impairment (Child-Pugh class C). Pregnant women, or women of childbearing potential not using reliable contraception during treatment and thereafter as long as plasma levels are above 0.02 mg/l. Breastfeeding women. Pregnancy must be excluded before start of treatment. Patients with severe immunodeficiency states, e.g. AIDS. Significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia. Severe active infection until resolution. Severe renal impairment undergoing dialysis, because insufficient clinical experience is available in this patient group. Severe hypoproteinaemia, e.g. in nephrotic syndrome.

Warnings and precautions: **Monitoring:** Before starting treatment: blood pressure, alanine aminotransferase (ALT/SGPT), complete blood cell count (CBC) including differential white blood cell (WBC) and platelet count. Pregnancy should be excluded. During treatment the following should be monitored: blood pressure periodically, ALT/SGPT assessed at least every 4 weeks for the first 6 months of treatment and regularly thereafter. Consider additional monitoring when AUBAGIO is given in patients with pre-existing liver disorders, given with other potentially hepatotoxic drugs or as indicated by clinical symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. Liver enzymes should be assessed every 2 weeks during the first 6 months of treatment, and at least every 8 weeks thereafter for at least 2 years from initiation of treatment. For ALT (SGPT) elevations between 2- and 3-fold the upper limit of normal, monitoring must be performed weekly. CBC should be performed based on clinical signs and symptoms.

Accelerated elimination procedure (AEP): Without an AEP, it takes an average of 8 months to reach plasma concentrations less than 0.02 mg/l and may take up to 2 years. An AEP can be used at any time after discontinuation of teriflunomide. **Hepatic effects:** Elevations of liver enzymes have been observed in patients receiving teriflunomide. These elevations occurred mostly within the first 6 months of treatment. Cases of drug-induced liver injury (DILI) have been observed during treatment with teriflunomide, sometimes life-threatening. Most cases of DILI occurred with time to onset of several weeks or several months after treatment initiation of teriflunomide, but DILI can also occur with prolonged use. The risk for liver enzyme increases and DILI with teriflunomide might be higher in patients with pre-existing liver disorder, concomitant treatment with other hepatotoxic drugs, and/or consumption of substantial quantities of alcohol. Patients should be closely monitored for signs and symptoms of liver injury. Teriflunomide therapy should be discontinued and accelerated elimination procedure considered if liver injury is suspected. If liver enzymes are confirmed as >3x ULN, teriflunomide therapy should be discontinued. In case of treatment discontinuation, liver tests should be pursued until normalisation of transaminase levels.

Infections: Patients receiving AUBAGIO should be instructed to report symptoms of infections to a physician. Patients with active acute or chronic infections should not start treatment with AUBAGIO until the infection(s) is resolved. Patients tested positive in tuberculosis screening should be treated by standard medical practice prior to therapy. **Respiratory reactions:** Interstitial lung disease (ILD) as well as cases of pulmonary hypertension have been reported with teriflunomide in the post-marketing setting. The risk might be increased in patients with a history of ILD. Due to the potential risk of ILD, pulmonary symptoms, such as persistent cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. **Haematological effects:** A mean decrease of <15% from baseline affecting WBC counts have been observed. Obtain CBC including differential white blood cell count and platelets prior to initiation of treatment, thereafter CBC should be assessed as indicated by clinical signs and symptoms. Patients with pre-existing cytopenias may have a higher risk of haematological disorders. In cases of severe haematological reactions, including pancytopenia, AUBAGIO and all concomitant myelosuppressive treatment must be discontinued and the AEP be considered. **Skin reactions:** Cases of serious skin reactions, sometimes fatal, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with AUBAGIO. If skin and /or mucosal reactions (ulcerative stomatitis) are observed which raise the suspicion of severe generalised major skin reactions, teriflunomide must be discontinued and an accelerated procedure initiated immediately. New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during the use of teriflunomide. Treatment withdrawal and initiation of an AEP may be considered. **Peripheral neuropathy:** Discontinuing AUBAGIO therapy and performing the AEP should be considered. **Vaccination:** Live attenuated vaccines should be avoided. **Interference with determination of ionised calcium levels:** The measurement of ionised calcium levels might show falsely decreased values under treatment with teriflunomide. The plausibility of observed values should be questioned and in case of doubtful measurements, it is recommended to determine the total albumin adjusted serum calcium concentration. **Immunosuppressive/Immunomodulating therapies:** Co-administration with leflunomide is not recommended. Co-administration with antineoplastic or immunosuppressive therapies has not been evaluated. **SWITCHING to/from AUBAGIO:** No waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate. Due to the risk of concomitant immune effects for up to 2-3 months, caution is required when switching patients immediately from natalizumab to teriflunomide. To avoid concomitant immune effects when switching from fingolimod, 10-14 weeks is needed for lymphocytes to return to the normal range. If a decision is made to stop treatment with AUBAGIO, during the interval of 5 half-lives (approximately 3.5 months, although may be longer in some patients), starting other therapies will result in concomitant exposure to AUBAGIO. This may lead to an additive effect on the immune system and caution is, therefore, indicated. **Paediatric population:** Cases of pancreatitis have been observed. Clinical symptoms included abdominal pain, nausea and/or vomiting. Serum amylase and lipase were elevated in these patients. The time to onset ranged from a few months up to three years. Patients should be informed of the characteristic symptoms of pancreatitis. If pancreatitis is suspected, pancreatic enzymes and related laboratory parameters should be obtained. If pancreatitis is confirmed, teriflunomide should be discontinued and an accelerated elimination procedure should be initiated. **Lactose:** Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product. **Sodium:** This medicine contains less than 1 mmol sodium (23 mg per tablet), that is to say essentially "sodium free". **Interactions:** Rifampicin and other known potent CYP and transporter inducers; medicinal products metabolised by CYP1A2 or CYP2C8; substrates of OAT3; substrates of BCRP and the OATP family, especially HMG-Co reductase inhibitors, should be used with caution during the treatment with teriflunomide. Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered. Co-administration with cholestyramine or activated

charcoal is not recommended unless an accelerated elimination is desired. Whilst the interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, it should be considered when selecting or adjusting oral contraceptive treatment. A 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was co-administered with warfarin as compared with warfarin alone. Close INR follow-up and monitoring is recommended.

Pregnancy and lactation: Women of childbearing potential must use effective contraception during treatment and after treatment as long as teriflunomide plasma concentration is >0.02 mg/l. Female children and/or parents/caregivers of female children should be informed about the need to contact the treating physician once the female child under AUBAGIO treatment experiences menses. Counselling should be provided to the new patients of child-bearing potential about contraception and the potential risk to the foetus. Referral to a gynaecologist should be considered. Plans to stop or change contraception, or in the case of suspected pregnancy, patient must discontinue AUBAGIO and notify the physician immediately. In case of pregnancy, the physician and patient must discuss the risk to the pregnancy and the AEP. In women wishing to become pregnant, teriflunomide should be stopped and an AEP is recommended. Please see SmPC for more details. Lactation is contraindicated. **Adverse effects: Very common (≥1/10):** Headache, diarrhoea, nausea, alopecia and ALT increase. **Common (≥1/100 to <1/10):** Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, pharyngitis, cystitis, gastroenteritis viral, oral herpes, tooth infection, laryngitis, tinea pedis, neutropenia, anaemia, mild allergic reactions, anxiety, paraesthesia, sciatica, carpal tunnel syndrome, palpitations, hypertension, pancreatitis in the paediatric population, upper abdominal pain, vomiting, toothache, Gamma-glutamyltransferase increase, aspartate aminotransferase increase, rash, acne, musculoskeletal pain, myalgia, arthralgia, pollakiuria, menorrhagia, pain, asthenia, weight decrease, neutrophil count decrease, WBC decrease and blood creatine phosphokinase increase.

Uncommon (≥1/1000 to <1/100): Severe infections including sepsis, mild thrombocytopenia (platelets <100G/l), hypersensitivity reactions (immediate or delayed) including anaphylaxis and angioedema, hyperaesthesia, neuralgia, peripheral neuropathy, interstitial lung disease, pancreatitis in the adult population, stomatitis, colitis, dyslipidaemia, nail disorders psoriasis (including pustular), severe skin reactions and post-traumatic pain. **Rare:** (≥1/10,000 to <1/1,000): Acute hepatitis. **Frequency not known:** Pulmonary hypertension, drug-induced liver injury (DILI). Please see SPC for full details. **Legal Classification:** POM. **List Price: GB:** £1037.84 (28x tablets). **Marketing authorisation number:** PLGB 04425/0819. **Marketing authorisation holder:** Aventis Pharma Ltd, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. **For more information please contact:** Medical Information, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. Or uk-medicalinformation@sanofi.com.

Date of Preparation: December 2023.

Adverse events should be reported.
Reporting forms and information can be found at:
In the UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902314. Alternatively, send via email to UK-drugsafety@sanofi.com

AUBAGIO® PRESCRIBING INFORMATION – IE & NI

Prescribing Information: AUBAGIO® 14 mg (teriflunomide) film-coated tablets

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each film-coated tablet contains 14 mg of teriflunomide.

Indication: AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS).

Dosage and administration: The treatment should be initiated and supervised by a physician experienced in the management of MS. In adults, the recommended dose of teriflunomide is 14 mg once daily. In paediatric patients (10 years of age and above), the recommended dose is 14 mg once daily with body weight >40 kg. AUBAGIO should be taken orally and swallowed whole with some water. AUBAGIO can be taken with or without food. **Elderly (≥65 years):** AUBAGIO should be used with caution due to insufficient data on safety and efficacy. **Renal impairment:** No dose adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis. **Hepatic impairment:** No dose adjustment is necessary for patients with mild and moderate hepatic impairment. **Paediatric:** The safety and efficacy in children aged below 10 years have not been established. No data are available.

Contraindications: Hypersensitivity to the active ingredient or excipients. Patients with severe hepatic impairment (Child-Pugh class C). Pregnant women, or women of childbearing potential not using reliable contraception during treatment and thereafter as long as plasma levels are above 0.02 mg/l. Breastfeeding women. Pregnancy must be excluded before start of treatment. Patients with severe immunodeficiency states, e.g. AIDS, significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia. Severe active infection until resolution. Severe renal impairment undergoing dialysis, because insufficient clinical experience is available in this patient group. Severe hypoproteinaemia, e.g. in nephrotic syndrome.

Warnings and precautions: **Monitoring:** Before starting treatment: blood pressure, alanine aminotransferase (ALT/SGPT), complete blood cell count (CBC) including differential white blood cell (WBC) and platelet count. Pregnancy should be excluded. During treatment the following should be monitored: blood pressure periodically, ALT/SGPT assessed at least every 4 weeks for the first 6 months of treatment and regularly thereafter. Consider additional monitoring when AUBAGIO is given in patients with pre-existing liver disorders, given with other potentially hepatotoxic drugs or as indicated by clinical symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. Liver enzymes should be assessed every 2 weeks during the first 6 months of treatment, and at least every 8 weeks thereafter for at least 2 years from initiation of treatment. For ALT (SGPT) elevations between 2- and 3-fold the upper limit of normal, monitoring must be performed weekly. CBC should be performed based on clinical signs and symptoms. **Accelerated elimination procedure (AEP):** Without an AEP, it takes an average of 8 months to reach plasma concentrations less than 0.02 mg/l and may take up to 2 years. An AEP can be used at any time after discontinuation of teriflunomide. **Hepatic effects:** Elevations of liver enzymes have been observed in patients receiving teriflunomide. These elevations occurred mostly within the first 6 months of treatment. Cases of drug-induced liver injury (DILI) have been observed during treatment with teriflunomide, sometimes life-threatening. Most cases of DILI occurred with time to onset of several weeks or several months after treatment initiation of teriflunomide, but DILI can also occur with prolonged use. The risk for liver enzyme increases and DILI with teriflunomide might be higher in patients with preexisting liver disorder, concomitant treatment with other hepatotoxic drugs, and/or consumption of substantial quantities of alcohol. Patients should be closely monitored for signs and symptoms of liver injury. Teriflunomide therapy should be discontinued and accelerated elimination procedure considered if liver injury is suspected. If liver enzymes are confirmed as >3x ULN, teriflunomide should be discontinued. In case of treatment discontinuation, liver tests should be pursued until normalisation of transaminase levels. **Infections:** Patients receiving AUBAGIO should be instructed to report symptoms of infections to a physician. Patients with active acute or chronic infections should not start treatment with AUBAGIO until the infection(s) is resolved. Patients tested positive in tuberculosis screening

should be treated by standard medical practice prior to therapy. **Respiratory reactions:** Interstitial lung disease (ILD) as well as cases of pulmonary hypertension have been reported with teriflunomide in the postmarketing setting. The risk might be increased in patients with a history of ILD. Due to the potential risk of ILD, pulmonary symptoms, such as persistent cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. **Haematological effects:** A mean decrease of <15% from baseline affecting WBC counts have been observed. Obtain CBC including differential white blood cell count and platelets prior to initiation of treatment, thereafter CBC should be assessed as indicated by clinical signs and symptoms. Patients with pre-existing cytopenias may have a higher risk of haematological disorders. In cases of severe haematological reactions, including pancytopenia, AUBAGIO and all concomitant myelosuppressive treatment must be discontinued and the AEP be considered. **Skin reactions:** Cases of serious skin reactions, sometimes fatal, (including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)) and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with AUBAGIO. If skin and/or mucosal reactions (ulcerative stomatitis) are observed which raise the suspicion of severe generalised major skin reactions, teriflunomide must be discontinued and an accelerated procedure initiated immediately. New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during the use of teriflunomide. Treatment withdrawal and initiation of an AEP may be considered. **Peripheral neuropathy:** Discontinuing AUBAGIO therapy and performing the AEP should be considered. **Vaccination:** Live attenuated vaccines should be avoided. **Interference with determination of ionised calcium levels:** The measurement of ionised calcium levels might show falsely decreased values under treatment with teriflunomide. The plausibility of observed values should be questioned and in case of doubtful measurements, it is recommended to determine the total albumin adjusted serum calcium concentration. **Immunosuppressive/immunomodulating therapies:** Co-administration with leflunomide is not recommended. Co-administration with antineoplastic or immunosuppressive therapies has not been evaluated. **SWITCHING to/from AUBAGIO:** No waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate. Due to the risk of concomitant immune effects for up to 2-3 months, caution is required when switching patients immediately from natalizumab to teriflunomide. To avoid concomitant immune effects when switching from fingolimod, 10-14 weeks is needed for lymphocytes to return to the normal range. If a decision is made to stop treatment with AUBAGIO, during the interval of 5 half-lives (approximately 3.5 months, although may be longer in some patients), starting other therapies will result in concomitant exposure to AUBAGIO. This may lead to an additive effect on the immune system and caution is, therefore, indicated. **Paediatric population:** **Cases of pancreatitis have been observed.** Clinical symptoms included abdominal pain, nausea and/or vomiting. Serum amylase and lipase were elevated in these patients. The time to onset ranged from a few months up to three years. Patients should be informed of the characteristic symptoms of pancreatitis. If pancreatitis is suspected, pancreatic enzymes and related laboratory parameters should be obtained. If pancreatitis is confirmed, teriflunomide should be discontinued and an accelerated elimination procedure should be initiated. **Lactose:** Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product. **Sodium:** This medicine contains less than 1 mmol sodium (23 mg per tablet), that is to say essentially "sodium free". **Interactions:** Rifampicin and other known potent CYP and transporter inducers; medicinal products metabolised by CYP1A2 or CYP2C8; substrates of OAT3; substrates of BCRP and the OATP family, especially HMG-Co reductase inhibitors, should be used with caution during the treatment with teriflunomide. Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered. Co-administration with cholestyramine or activated charcoal is not recommended unless an accelerated elimination is desired. Whilst the interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, it should be considered when selecting or adjusting oral contraceptive

treatment. A 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was co-administered with warfarin as compared with warfarin alone. Close INR follow-up and monitoring is recommended. **Pregnancy and lactation:** Women of childbearing potential must use effective contraception during treatment and after treatment as long as teriflunomide plasma concentration is >0.02 mg/l. Female children and/or parents/caregivers of female children should be informed about the need to contact the treating physician once the female child under AUBAGIO treatment experiences menses. Counselling should be provided to the new patients of child-bearing potential about contraception and the potential risk to the foetus. Referral to a gynaecologist should be considered. Plans to stop or change contraception, or in the case of suspected pregnancy, patient must discontinue AUBAGIO and notify the physician immediately. In case of pregnancy, the physician and patient must discuss the risk to the pregnancy and the AEP. In women wishing to become pregnant, teriflunomide should be stopped and an AEP is recommended. Please see SmPC for more details. Lactation is contraindicated.

Adverse effects: Very common (≥1/10): Headache, diarrhoea, nausea, alopecia and ALT increase. **Common (≥1/100 to <1/10):** Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, pharyngitis, cystitis, gastroenteritis viral, oral herpes, tooth infection, laryngitis, tinea pedis, neutropenia, anaemia, mild allergic reactions, anxiety, paraesthesia, sciatica, carpal tunnel syndrome, palpitations, hypertension, pancreatitis in the paediatric population, upper abdominal pain, vomiting, toothache, Gamma-glutamyltransferase increase, aspartate aminotransferase increase, rash, acne, musculoskeletal pain, myalgia, arthralgia, pollakiuria, menorrhagia, pain, asthenia, weight decrease, neutrophil count decrease, WBC decrease and blood creatine phosphokinase increase. **Uncommon (≥1/1000 to <1/100):** Severe infections including sepsis, mild thrombocytopenia (platelets <100G/l), hypersensitivity reactions (immediate or delayed) including anaphylaxis and angioedema, hyperaesthesia, neuralgia, peripheral neuropathy, interstitial lung disease, pancreatitis in the adult population, stomatitis, colitis, dyslipidaemia, nail disorders, psoriasis (including pustular), severe skin reactions and post-traumatic pain. **Rare:** (≥1/10,000 to <1/1,000): Acute hepatitis. **Frequency not known:** Pulmonary hypertension, drug-induced liver injury (DILI). Please see SPC for full details.

Legal Classification: POM. **Price UK:** £1037.84 (28x tablets). **Marketing authorisation numbers:** EU/1/13/838/001-005. **Marketing authorisation holder:** Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 Gentilly, France. **For more information please contact:** UK: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK or ukmedicalinformation@sanofi.com. IE: Sanofi, 18 Riverwalk, Citywest Business Campus, Dublin 24. Tel: 01 403 5600, email: IEmedinfo@sanofi.com. **Date of preparation:** December 2022.

Adverse events should be reported.
Reporting forms and information can be found at:
www.mhra.gov.uk/yellowcard or search for MHRA
Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to
Sanofi Tel: 0800 0902314. Alternatively, send via email to
UK-drugsafety@sanofi.com

In Ireland: www.hpra.ie; email: medsafety@hpra.ie.
Adverse events should also be reported to Sanofi Ireland Ltd.
Tel: 01 403 5600. Alternatively, send via email to
IEPharmacovigilance@sanofi.com

LEMTRADA® ▽ PRESCRIBING INFORMATION – GB

LEMTRADA (alemtuzumab) 12mg concentrate for solution for infusion.

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each vial contains 12 mg alemtuzumab in 1.2 ml solution (10 mg/ml).

Indication: LEMTRADA is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or; Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Dosage and Administration: LEMTRADA treatment should only be initiated and supervised by a neurologist experienced in the treatment of patients with MS in a hospital with ready access to intensive care. Specialists and equipment required for the timely diagnosis and management of adverse reactions, especially myocardial ischaemia and myocardial infarction, cerebrovascular adverse reactions, autoimmune conditions and infections, should be available. Resources for the management of cytokine release syndrome, hypersensitivity and/or anaphylactic reactions should be available. The recommended dose of LEMTRADA is 12 mg/day administered by intravenous (IV) infusion for 2 initial, treatment courses, with up to 2 additional treatment courses if needed. Missed doses should not be given on the same day as a scheduled dose. The diluted LEMTRADA solution should be administered by IV infusion over a period of approximately 4 hours. **1st treatment course:** 12 mg/day on 5 consecutive days (60 mg total dose). **2nd treatment course:** 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the 1st treatment course. **Additional as-needed treatment course(s):** 3rd/4th: 12 mg/day on 3 consecutive days (36 mg total dose) administered at least 12 months after the prior treatment course. **Pre-treatment:** Patients should be pre-treated with corticosteroids immediately prior to LEMTRADA administration on each of the first 3 days of any treatment course. Additionally, pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered. Oral prophylaxis for herpes infection should be administered to all patients starting on the first day of each treatment course and continuing for a minimum of 1 month following treatment with LEMTRADA. **Follow-up of patients:** from initiation of the first treatment course and for at least 48 months after the last infusion of the second treatment course. If an additional third or fourth course is administered, continue safety follow-up for at least 48 months after the last infusion. **Special populations:** **Elderly:** Clinical studies did not include any patients aged over 61 years old. It has not been determined whether they respond differently than younger patients. **Renal or hepatic impairment:** No data available. **Paediatric (0-18 years):** No data available.

Contraindications: Patients with: Hypersensitivity to the active substance, or to any of the excipients. HIV infection. Severe active infection until complete resolution. Uncontrolled hypertension. A history of arterial dissection of the cervicocephalic arteries. A history of stroke. A history of angina pectoris or myocardial infarction. Known coagulopathy, on anti-platelet or anticoagulant therapy. Other concomitant autoimmune diseases (besides MS).

Precautions and warnings: LEMTRADA is not recommended for patients with inactive disease or those stable on current therapy. Patients treated with LEMTRADA must be given the Package Leaflet, the Patient Alert Card and the Patient Guide. Before treatment, patients must be informed about the risks, benefits, and the need to commit to follow up from treatment initiation for at least 48 months after the last infusion of LEMTRADA. Patients and physicians should be made aware of the potential later onset of adverse events after the 48 months monitoring period. Educate patients on the signs and symptoms of all conditions, and to seek immediate medical attention if any of these symptoms are observed. If confirmed, seek specialist advice. **Traceability:** In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. **Autoimmunity:** Treatment may result in the formation of

autoantibodies and increase the risk of autoimmune mediated conditions which may be serious and life threatening. Reported autoimmune conditions, include thyroid disorders, immune thrombocytopenic purpura (ITP), nephropathies including anti-glomerular basement membrane (anti-GBM) disease, autoimmune hepatitis (AIH), acquired haemophilia A, thrombotic thrombocytopenic purpura (TTP), sarcoidosis, and autoimmune encephalitis. Patients who develop autoimmunity should be assessed for other autoimmune mediated conditions. **Acquired haemophilia A:** Patients typically present with spontaneous subcutaneous haematomas and extensive bruising although haematuria, epistaxis, gastrointestinal or other types of bleeding may occur. A coagulopathy panel including aPTT must be obtained in all patients that present with such symptoms. In case of a prolonged aPTT patient should be referred to a haematologist. **TTP:** Development of TTP has been reported in patients treated with LEMTRADA during post-marketing use, including a fatal case. TTP is a serious condition that requires urgent evaluation and prompt treatment, and can develop several months after last LEMTRADA infusion. TTP may be characterised by thrombocytopenia, microangiopathic haemolytic anaemia, neurological symptoms, fever and renal impairment. **Autoimmune Encephalitis:** Cases of autoimmune encephalitis have been reported in patients treated with LEMTRADA. Autoimmune encephalitis is characterised by subacute onset (with rapid progression over months) of memory impairment, altered mental status or psychiatric symptoms, generally in combination with new onset focal neurological findings and seizures. Patients with suspected autoimmune encephalitis should have neuroimaging (MRI), EEG, lumbar puncture and serologic testing for appropriate biomarkers (e.g. neural autoantibodies) to confirm diagnosis and exclude alternative aetiologies. **ITP:** Symptoms could include (but are not limited to) easy bruising, petechiae, spontaneous mucocutaneous bleeding (e.g., epistaxis, haemoptysis), heavier than normal or irregular menstrual bleeding. Haemoptysis may also be indicative of anti-GBM disease, and an appropriate differential diagnosis has to be undertaken. Complete blood counts with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter until at least 48 months after the last infusion. After which, testing should be performed based on clinical findings suggestive of ITP. If ITP is suspected a complete blood count should be obtained immediately. If ITP is confirmed, appropriate medical intervention should be promptly initiated, including immediate referral to a specialist. **Cardiac disorders:** Congestive heart failure, cardiomyopathy, and decreased ejection fraction have been reported in alemtuzumab-treated non-MS patients previously treated with potentially cardiotoxic agents. **Nephropathies including anti-GBM disease:** Clinical manifestations of nephropathy may include elevation in serum creatinine, haematuria, and/or proteinuria. While not observed in clinical trials, alveolar haemorrhage manifested as haemoptysis may occur with anti-GBM disease. Haemoptysis may also be indicative of ITP or acquired haemophilia A and an appropriate differential diagnosis has to be undertaken. Anti-GBM disease may lead to renal failure requiring dialysis and/or transplantation if not treated rapidly and can be life-threatening if left untreated. Serum creatinine levels and urinalysis with microscopy should be obtained prior to initiation of treatment and at monthly intervals thereafter until at least 48 months after the last infusion. **Thyroid disorders:** Observed autoimmune thyroid disorders included hyperthyroidism or hypothyroidism. Most events were mild to moderate in severity. Regardless of pretreatment anti-TPO antibody status patients may develop a thyroid adverse reaction and must have all tests periodically performed as described above. Thyroid function tests should be obtained prior to initiation of treatment and every 3 months thereafter until 48 months following the last infusion. After this period of time testing should be performed based on clinical findings suggestive of thyroid dysfunction or in case of pregnancy. In the post-marketing setting several patients who developed biopsy proven auto-immune hepatitis had previously developed autoimmune thyroid disorders. **Cytopenia:** Use of LEMTRADA has been associated with suspected autoimmune cytopenias such as neutropenia, haemolytic anaemia and pancytopenia. FBC results should be used to monitor for cytopenias, including neutropenia. **Autoimmune hepatitis and hepatic injury:** Cases of autoimmune hepatitis (including fatal cases and

cases requiring liver transplantation) and hepatic injury related to infections have been reported in patients treated with LEMTRADA. Liver function tests should be performed before initial treatment and at monthly intervals until at least 48 months after the last infusion. **Haemophagocytic lymphohistiocytosis (HLH):** HLH (including fatal cases) have been reported in patients treated with LEMTRADA. HLH is a life-threatening syndrome of pathologic immune activation characterized by clinical signs and symptoms of extreme systemic inflammation, such as fever, hepatomegaly and cytopenias. It is associated with high mortality rates if not recognized early and treated. Symptoms have been reported to occur within a few months to four years following the initiation of treatment. Patients who develop early manifestations of pathologic immune activation should be evaluated immediately. **Infusion-Associated Reactions (IARs):** Most patients treated with LEMTRADA experienced mild to moderate IARs during and/or up to 24 hours after. Observe patients for IARs during and for at least 2 hours after LEMTRADA infusion. Extended observation time (hospitalization) should be considered, as appropriate. If severe infusion reactions occur, the intravenous infusion should be discontinued immediately. Resources for the management of anaphylaxis or serious reactions should be available. **Adult Onset Still's Disease (AOSD):** During post-marketing use, AOSD has been reported in patients treated with LEMTRADA. AOSD is a rare inflammatory condition that requires urgent evaluation and treatment. Patients with AOSD may have a combination of the following signs and symptoms: fever, arthritis, rash and leukocytosis in the absence of infections, malignancies, and other rheumatic conditions. Consider interruption or discontinuation of treatment with LEMTRADA if an alternate etiology for the signs or symptoms cannot be established. **Other serious reactions temporally associated with LEMTRADA infusion:** During post-marketing use, rare, serious, sometimes fatal and unpredictable adverse events from various organ systems (such as, haemorrhagic stroke; myocardial ischaemia and myocardial infarction; dissection of the cervico-cephalic arteries; pulmonary alveolar haemorrhage; thrombocytopenia; pericarditis; pneumonitis) have been reported. Reactions have occurred following any of the doses and also after course number 2. **Infusion instructions to reduce serious reactions temporally associated with LEMTRADA infusion: Pre-infusion:** Baseline ECG and vital signs, including heart rate and blood pressure measurement. Perform laboratory tests (complete blood count with differential, serum transaminases, serum creatinine, test of thyroid function and urinalysis with microscopy). **During infusion:** Perform continuous/frequent (at least every hour) monitoring of heart rate, blood pressure and overall clinical status of the patients. Discontinue the infusion; in case of a severe adverse event; if the patient shows clinical symptoms suggesting development of a serious adverse event associated with the infusion (myocardial ischemia, haemorrhagic stroke, cervico-cephalic arterial dissection or pulmonary alveolar haemorrhage). **Post-infusion:** Observation for infusion reactions is recommended for a minimum of 2 hours after LEMTRADA infusion. Patients with clinical symptoms suggesting development of a serious adverse event temporally associated with the infusion (myocardial ischemia, haemorrhagic stroke, cervico-cephalic arterial dissection or pulmonary alveolar haemorrhage) should be closely monitored until complete resolution of the symptoms. The observation time should be extended (hospitalisation) as appropriate. The patients should be educated on the potential for delayed onset of infusion associated reactions and instructed to report symptoms and seek appropriate medical care. Platelet count should be obtained immediately after infusion on Days 3 and 5 of the first infusion course, as well as immediately after infusion on Day 3 of any subsequent course. Clinically significant thrombocytopenia needs to be followed until resolution. Referral to a haematologist for management should be considered. **Serious infections included:** Appendicitis, gastroenteritis, herpes zoster, and tooth infection were seen during clinical trials. Infections were generally of typical duration and resolved following conventional medical treatment. Serious varicella zoster virus infections, including primary varicella and varicella zoster re-activation, Cervical human papilloma virus (HPV) infection, including cervical dysplasia and anogenital warts have been reported. It is recommended that HPV screening be completed annually for female patients. Cytomegalovirus infections (CMV)

LEMTRADA® ▽ PRESCRIBING INFORMATION – GB CONTINUED

including cases of CMV reactivation have been reported. Most cases occurred within 2 months of alemtuzumab dosing. Before initiation of therapy, evaluation of immune serostatus could be considered according to local guidelines. Epstein-Barr virus (EBV) infection, including reactivation, and severe and sometimes fatal EBV hepatitis cases, has been reported. Active and latent tuberculosis (TB), including a few cases of disseminated tuberculosis, have been reported. Before initiation of therapy, all patients must be evaluated for both active or inactive ("latent") tuberculosis infection, according to local guidelines. Listeriosis/Listeria meningitis has been reported in LEMTRADA treated patients, generally within one month of LEMTRADA infusion. To reduce the risk of infection, patients receiving LEMTRADA should avoid ingestion of uncooked or undercooked meats, soft cheeses and unpasteurized dairy products two weeks prior to, during, and for at least one month after LEMTRADA infusion. Superficial fungal infections, especially oral and vaginal candidiasis, was reported. Pneumonitis has been reported in patients who received LEMTRADA infusions. Most cases occurred within the first month after treatment with LEMTRADA.

Immunomodulation: As with other immunomodulating therapies, potential combined effects on the patient's immune system should be taken into account when considering administration of LEMTRADA, due to the potential increase risk of immunosuppression. Screening patients at high risk of HBV and/or HCV infection before initiation of LEMTRADA should be considered and caution should be exercised in prescribing LEMTRADA to patients identified as carriers. **Progressive Multifocal Leukoencephalopathy (PML):** Rare cases of PML (including fatal), have been reported in MS patients after treatment with alemtuzumab. Patients treated with alemtuzumab must be monitored for any signs that may be suggestive of PML (e.g. cognitive, neurological or psychiatric symptoms). If a diagnosis of PML has been made, treatment with alemtuzumab should not be started or restarted. **Acute acalculous cholecystitis (AAC):** LEMTRADA may increase the risk of AAC. Cases of AAC have been reported in LEMTRADA-treated patients during post marketing. Time to onset of symptoms ranged from <24 hours-2 months after infusion. Symptoms include abdominal pain, abdominal tenderness, fever, nausea, and vomiting. AAC may be associated with high morbidity and mortality rates if not diagnosed early and treated. If suspected, evaluate and treat promptly. **Malignancy:** As with other immunomodulatory therapies, caution advised when initiating treatment in patients with pre-existing and/or on-going malignancy. **Vaccination:** It is recommended that patients have completed local immunisation requirements ≥ 6 weeks prior to treatment with LEMTRADA. Live viral vaccines should not be administered following a course of LEMTRADA. Varicella zoster virus vaccination of antibody-negative patients should be considered ≥ 6 weeks prior to treatment initiation. **Fertility, pregnancy and lactation:** Women of childbearing potential have to use effective contraception during and for 4 months following a course of

LEMTRADA. There is a limited data from the use in pregnant women. LEMTRADA should be administered during pregnancy only if the potential benefit justifies the potential risk to the foetus. Animal studies have shown reproductive toxicity. Special risks are associated with thyroid disorders in pregnant women. Untreated hypothyroidism in pregnant women increases miscarriage risk and foetal effects (e.g. mental retardation, dwarfism). Pregnant women with Graves' disease may transfer thyroid stimulating hormone receptor antibodies to foetus so may cause transient neonatal Graves' disease. Discontinue breastfeeding during LEMTRADA treatment and for 4 months following that course. Benefits of breastfeeding may outweigh potential risks of LEMTRADA exposure. Animal data have shown effects on fertility in humanised mice however a potential impact on human fertility during the period of exposure is unknown based on the available data. **Interactions:** In a controlled clinical trial, MS patients recently treated with beta interferon and glatiramer acetate, were required to discontinue treatment 28 days before initiating treatment with LEMTRADA.

Adverse reactions: **Very common ($\geq 1/10$):** Upper respiratory tract infection, urinary tract infection, Herpes virus infection, lymphopenia, leukopenia, (including neutropenia), Basedow's disease, hyperthyroidism, hypothyroidism, headache, tachycardia, flushing, nausea, urticaria, rash, pruritus, generalised rash, pyrexia, fatigue, chills. **Common ($\geq 1/100 < 1/10$):** Herpes Zoster infection, lower respiratory tract infections, gastroenteritis, oral candidiasis, vulvovaginal candidiasis, influenza, ear infection, pneumonia, vaginal infection, tooth infection, skin papilloma, lymphadenopathy, immune thrombocytopenic purpura, thrombocytopenia, anaemia, haematocrit decreased, leukocytosis, cytokine release syndrome, hypersensitivity including anaphylaxis, autoimmune thyroiditis, goitre, anti-thyroid antibody positive, insomnia, anxiety, depression, MS relapse, dizziness, hypoaesthesia, paraesthesia, tremor, dysgeusia, migraine, conjunctivitis, endocrine ophthalmopathy, vision blurred, vertigo, bradycardia, palpitations, hypotension, hypertension, dyspnoea, cough, epistaxis, hiccups, oropharyngeal pain, asthma, abdominal pain, vomiting, diarrhoea dyspepsia, stomatitis, aspartate aminotransferase increased, alanine aminotransferase increase, erythema, ecchymosis, alopecia, hyperhidrosis, acne, skin lesion, dermatitis, myalgia, muscle weakness, arthralgia, back pain, pain in extremity, muscle spasms, neck pain, musculoskeletal pain, proteinuria, haematuria, menorrhagia, menstruation irregular, chest discomfort, pain, oedema peripheral, asthenia, influenza-like illness, malaise, infusion site pain, blood creatinine increased, contusion and infusion related reaction. **Uncommon ($\geq 1/1,000 < 1/100$):** Onychomycosis, gingivitis, fungal skin infection, tonsillitis, acute sinusitis, cellulitis, tuberculosis, cytomegalovirus infection, pancytopenia, haemolytic anaemia, acquired haemophilia A, sarcoidosis, decreased appetite, sensory disturbance, hyperaesthesia, tension headache, autoimmune encephalitis, diplopia, ear pain, atrial fibrillation, throat tightness,

throat irritation, pneumonitis, constipation, gastro-oesophageal reflux disease, gingival bleeding, dry mouth, dysphagia, gastrointestinal disorder, haematochezia, cholecystitis including acalculous cholecystitis and AAC. Blister, night sweats, swelling face, eczema, vitiligo, alopecia areata, musculoskeletal stiffness, limb discomfort, nephrolithiasis, ketonuria, nephropathies including anti-GBM disease, cervical dysplasia, amenorrhoea, weight decreased, weight increased, red blood cell count decreased, bacterial test positive, blood glucose increased and mean cell volume increase. **Rare ($\geq 1/10,000 < 1/1,000$):** Haemophagocytic lymphohistiocytosis and thrombotic thrombocytopenic purpura. **Unknown:** Listeriosis/Listeria meningitis, EBV infection (including reactivation), Haemorrhagic stroke, cervicocephalic arterial dissection, myocardial ischaemia, myocardial infarction, Pulmonary alveolar haemorrhage, autoimmune hepatitis and hepatitis (associated with EBV infection), Adult Onset Still's Disease. **Please refer to the SmPC for full details on adverse reactions. List Price: £7,045 per 12mg vial. Legal category: POM. Marketing Authorisation Number: PLGB 04425/0787. Marketing Authorisation Holder: Aventis Pharma Ltd, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. Further information is available from: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK or contact uk-medicalinformation@sanofi.com SmPC Date: 11/08/2023 Date of preparation: August 2023**

Adverse events should be reported.
Reporting forms and information can be found at:
www.mhra.gov.uk/yellowcard or search for MHRA
Yellow Card in the Google Play or Apple App Store.

**Adverse events should also be reported to the Sanofi
Drug Safety department on Tel: 0800 0902314. Alternatively,
send via email to UK-drugsafety@sanofi.com**

LEMTRADA® ▽ PRESCRIBING INFORMATION – IE & NI

LEMTRADA (alemtuzumab) 12mg concentrate for solution for infusion

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each vial contains 12 mg alemtuzumab in 1.2 ml solution (10 mg/ml).

Indication: LEMTRADA is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or; Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Dosage and Administration: LEMTRADA treatment should only be initiated and supervised by a neurologist experienced in the treatment of patients with MS in a hospital with ready access to intensive care. Specialists and equipment required for the timely diagnosis and management of adverse reactions, especially myocardial ischaemia and myocardial infarction, cerebrovascular adverse reactions, autoimmune conditions and infections, should be available. Resources for the management of cytokine release syndrome, hypersensitivity and/or anaphylactic reactions should be available. The recommended dose of LEMTRADA is 12 mg/day administered by intravenous (IV) infusion for 2 initial, treatment courses, with up to 2 additional treatment courses if needed. Missed doses should not be given on the same day as a scheduled dose. The diluted LEMTRADA solution should be administered by IV infusion over a period of approximately 4 hours. **1st treatment course:** 12 mg/day on 5 consecutive days (60 mg total dose). **2nd treatment course:** 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the 1st treatment course. **Additional as-needed treatment course(s):** 12 mg/day on 3 consecutive days (36 mg total dose) administered at least 12 months after the prior treatment course. **Pre-treatment:** Patients should be pre-treated with corticosteroids immediately prior to LEMTRADA administration on each of the first 3 days of any treatment course. Additionally, pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered. Oral prophylaxis for herpes infection should be administered to all patients starting on the first day of each treatment course and continuing for a minimum of 1 month following treatment with LEMTRADA. **Follow-up of patients:** from initiation of the first treatment course and for at least 48 months after the last infusion of the second treatment course. If an additional third or fourth course is administered, continue safety follow-up for at least 48 months after the last infusion. **Special populations:** **Elderly:** Clinical studies did not include any patients aged over 61 years old. It has not been determined whether they respond differently than younger patients. **Renal or hepatic impairment:** No data available. **Paediatric (0-18 years):** No data available.

Contraindications: Patients with: Hypersensitivity to the active substance, or to any of the excipients. HIV infection. Severe active infection until complete resolution. Uncontrolled hypertension. A history of arterial dissection of the cervicocephalic arteries. A history of stroke. A history of angina pectoris or myocardial infarction. Known coagulopathy, on antiplatelet or anticoagulant therapy. Other concomitant autoimmune diseases (besides MS).

Precautions and warnings: LEMTRADA is not recommended for patients with inactive disease or those stable on current therapy. Patients treated with LEMTRADA must be given the Package Leaflet, the Patient Alert Card and the Patient Guide. Before treatment, patients must be informed about the risks, benefits, and the need to commit to follow up from treatment initiation for at least 48 months after the last infusion of LEMTRADA. Patients and physicians should be made aware of the potential later onset of adverse events after the 48 months monitoring period. Educate patients on the signs and symptoms of all conditions, and to seek immediate medical attention if any of these symptoms are observed. If confirmed, seek specialist advice. **Traceability:** In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. **Autoimmunity:** Treatment may result in the formation of

autoantibodies and increase the risk of autoimmune mediated conditions which may be serious and life threatening. Reported autoimmune conditions, include thyroid disorders, Immune Thrombocytopenic Purpura (ITP), nephropathies including anti-Glomerular Basement Membrane (anti-GBM) disease, autoimmune hepatitis (AIH), acquired haemophilia A, thrombotic thrombocytopenic purpura (TTP), sarcoidosis, and autoimmune encephalitis (AIE). Patients who develop autoimmunity should be assessed for other autoimmune mediated conditions. **Acquired haemophilia A:** Patients typically present with spontaneous subcutaneous haematomas and extensive bruising although haematuria, epistaxis, gastrointestinal or other types of bleeding may occur. A coagulopathy panel including aPTT must be obtained in all patients that present with such symptoms. In case of a prolonged aPTT patient should be referred to a haematologist. **TTP:** Development of TTP has been reported in patients treated with LEMTRADA during post-marketing use, including a fatal case. TTP is a serious condition that requires urgent evaluation and prompt treatment, and can develop several months after last LEMTRADA infusion. TTP may be characterized by thrombocytopenia, microangiopathic haemolytic anaemia, neurological symptoms, fever and renal impairment. **AIE:** Cases of AIE have been reported in patients treated with LEMTRADA. AIE is characterised by subacute onset (with rapid progression over months) of memory impairment, altered mental status or psychiatric symptoms, generally in combination with new onset focal neurological findings and seizures. Patients with suspected AIE should have neuroimaging (MRI), EEG, lumbar puncture and serologic testing for appropriate biomarkers (e.g. neural autoantibodies) to confirm diagnosis and exclude alternative etiologies. **ITP:** Symptoms could include (but are not limited to) easy bruising, petechiae, spontaneous mucocutaneous bleeding (e.g., epistaxis, haemoptysis), heavier than normal or irregular menstrual bleeding. Haemoptysis may also be indicative of anti-GBM disease, and an appropriate differential diagnosis has to be undertaken. Complete blood counts with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter until at least 48 months after the last infusion. After which, testing should be performed based on clinical findings suggestive of ITP. If ITP is suspected a complete blood count should be obtained immediately. If ITP is confirmed, appropriate medical intervention should be promptly initiated, including immediate referral to a specialist. **Cardiac disorders:** Congestive heart failure, cardiomyopathy, and decreased ejection fraction have been reported in alemtuzumab-treated non-MS patients previously treated with potentially cardiotoxic agents. **Nephropathies including anti-GBM disease:** Clinical manifestations of nephropathy may include elevation in serum creatinine, haematuria, and/or proteinuria. While not observed in clinical trials, alveolar haemorrhage manifested as haemoptysis may occur with anti-GBM disease. Haemoptysis may also be indicative of ITP or acquired haemophilia A and an appropriate differential diagnosis has to be undertaken. Anti-GBM disease may lead to renal failure requiring dialysis and/or transplantation if not treated rapidly and can be life-threatening if left untreated. Serum creatinine levels and urinalysis with microscopy should be obtained prior to initiation of treatment and at monthly intervals thereafter until at least 48 months after the last infusion. **Thyroid disorders:** Observed autoimmune thyroid disorders included hyperthyroidism or hypothyroidism. Most events were mild to moderate in severity. Regardless of pretreatment anti-TPO antibody status patients may develop a thyroid adverse reaction and must have all tests periodically performed as described above. Thyroid function tests should be obtained prior to initiation of treatment and every 3 months thereafter until 48 months following the last infusion. After this period of time testing should be performed based on clinical findings suggestive of thyroid dysfunction or in case of pregnancy. In the post-marketing setting several patients who developed biopsy proven auto-immune hepatitis had previously developed autoimmune thyroid disorders. **Cytopenia:** Use of LEMTRADA has been associated with suspected autoimmune cytopenias such as neutropenia, haemolytic anaemia and pancytopenia. FBC results should be used to monitor for cytopenias, including neutropenia. **Autoimmune hepatitis and hepatic injury:** Cases of autoimmune hepatitis (including fatal cases and cases requiring liver transplantation) and hepatic injury related to infections have been reported in

patients treated with LEMTRADA. Liver function tests should be performed before initial treatment and at monthly intervals until at least 48 months after the last infusion. **Haemophagocytic lymphohistiocytosis (HLH):** HLH (including fatal cases) have been reported in patients treated with LEMTRADA. HLH is a life-threatening syndrome of pathologic immune activation characterized by clinical signs and symptoms of extreme systemic inflammation, such as fever, hepatomegaly and cytopenias. It is associated with high mortality rates if not recognized early and treated. Symptoms have been reported to occur within a few months to four years following the initiation of treatment. Patients who develop early manifestations of pathologic immune activation should be evaluated immediately. **Infusion-Associated Reactions (IARs):** Most patients treated with LEMTRADA experienced mild to moderate IARs during and/or up to 24 hours after. Observe patients for IARs during and for at least 2 hours after LEMTRADA infusion. Extended observation time (hospitalization) should be considered, as appropriate. If severe infusion reactions occur, the intravenous infusion should be discontinued immediately. Resources for the management of anaphylaxis or serious reactions should be available. **Adult Onset Still's disease (AOSD):** During postmarketing use, AOSD has been reported in patients treated with LEMTRADA. AOSD is a rare inflammatory condition that requires urgent evaluation and treatment. Patients with AOSD may have a combination of the following signs and symptoms: fever, arthritis, rash and leukocytosis in the absence of infections, malignancies, and other rheumatic conditions. Consider interruption or discontinuation of treatment with LEMTRADA if an alternate etiology for the signs or symptoms cannot be established. **Other serious reactions temporally associated with LEMTRADA infusion:** During post-marketing use, rare, serious, sometimes fatal and unpredictable adverse events from various organ systems (such as, haemorrhagic stroke; myocardial ischaemia and myocardial infarction; dissection of the cervicocephalic arteries; pulmonary alveolar haemorrhage; thrombocytopenia; Pericarditis) have been reported. Reactions have occurred following any of the doses and also after course number 2. Pneumonitis has been reported in patients who received LEMTRADA infusions. Most cases occurred within the first month after treatment with LEMTRADA. **Infusion instructions to reduce serious reactions temporally associated with LEMTRADA infusion:** **Pre-infusion:** Baseline ECG and vital signs, including heart rate and blood pressure measurement. Perform laboratory tests (complete blood count with differential, serum transaminases, serum creatinine, test of thyroid function and urinalysis with microscopy). **During infusion:** Perform continuous/frequent (at least every hour) monitoring of heart rate, blood pressure and overall clinical status of the patients. Discontinue the infusion; in case of a severe adverse event; if the patient shows clinical symptoms suggesting development of a serious adverse event associated with the infusion (myocardial ischemia, haemorrhagic stroke, cervicocephalic arterial dissection or pulmonary alveolar haemorrhage). Post-infusion: Observation for infusion reactions is recommended for a minimum of 2 hours after LEMTRADA infusion. Patients with clinical symptoms suggesting development of a serious adverse event temporally associated with the infusion (myocardial ischemia, haemorrhagic stroke, cervicocephalic arterial dissection or pulmonary alveolar haemorrhage) should be closely monitored until complete resolution of the symptoms. The observation time should be extended (hospitalisation) as appropriate. The patients should be educated on the potential for delayed onset of infusion associated reactions and instructed to report symptoms and seek appropriate medical care. Platelet count should be obtained immediately after infusion on Days 3 and 5 of the first infusion course, as well as immediately after infusion on Day 3 of any subsequent course. Clinically significant thrombocytopenia needs to be followed until resolution. Referral to a haematologist for management should be considered. **Serious infections included:** Appendicitis, gastroenteritis, pneumonia, herpes zoster, and tooth infection were seen during clinical trials. Infections were generally of typical duration and resolved following conventional medical treatment. Serious varicella zoster virus infections, including primary varicella and varicella zoster re-activation, Cervical human papilloma virus (HPV) infection, including cervical dysplasia and anogenital warts have been reported. It is recommended that HPV screening be completed

LEMTRADA® ▽ PRESCRIBING INFORMATION – IE & NI CONTINUED

annually for female patients. Cytomegalovirus infections (CMV) including cases of CMV reactivation have been reported. Most cases occurred within 2 months of alemtuzumab dosing. Before initiation of therapy, evaluation of immune serostatus could be considered according to local guidelines. Epstein-Barr virus (EBV) infection, including reactivation, and severe and sometimes fatal EBV hepatitis cases, has been reported. Active and latent tuberculosis (TB), including a few cases of disseminated tuberculosis, have been reported. Before initiation of therapy, all patients must be evaluated for both active or inactive ("latent") tuberculosis infection, according to local guidelines. Listeriosis/Listeria meningitis has been reported in LEMTRADA treated patients, generally within one month of LEMTRADA infusion. To reduce the risk of infection, patients receiving LEMTRADA should avoid ingestion of uncooked or undercooked meats, soft cheeses and unpasteurized dairy products two weeks prior to, during, and for at least one month after LEMTRADA infusion. Superficial fungal infections, especially oral and vaginal candidiasis, was reported. **Immunomodulation:** As with other immunomodulating therapies, potential combined effects on the patient's immune system should be taken into account when considering administration of LEMTRADA, due to the potential increase risk of immunosuppression. Screening patients at high risk of HBV and/or HCV infection before initiation of LEMTRADA should be considered and caution should be exercised in prescribing LEMTRADA to patients identified as carriers. **Progressive Multifocal Leukoencephalopathy (PML):** Rare cases of PML (including fatal), have been reported in MS patients after treatment with alemtuzumab. Patients treated with alemtuzumab must be monitored for any signs that may be suggestive of PML (e.g. cognitive, neurological or psychiatric symptoms). If a diagnosis of PML has been made, treatment with alemtuzumab should not be started or restarted. **Acute acalculous cholecystitis (AAC):** LEMTRADA may increase the risk of AAC. Cases of AAC have been reported in LEMTRADA-treated patients during post marketing. Time to onset of symptoms ranged from <24 hours-2 months after infusion. Symptoms include abdominal pain, abdominal tenderness, fever, nausea, and vomiting. AAC may be associated with high morbidity and mortality rates if not diagnosed early and treated. If suspected, evaluate and treat promptly. **Malignancy:** As with other immunomodulatory therapies, caution advised when initiating treatment in patients with pre-existing and/or on-going malignancy. **Vaccination:** It is recommended that patients have completed local immunisation requirements ≥ 6 weeks prior to treatment with LEMTRADA. Live viral vaccines should not be administered following a course of LEMTRADA. Varicella zoster virus vaccination of antibodynegative patients should be considered ≥ 6 weeks prior to treatment initiation. **Fertility, pregnancy and lactation:** Women of childbearing potential have to use effective contraception during and for 4 months following a course of LEMTRADA. There is a limited data from the use in pregnant women. LEMTRADA should be administered during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Animal studies have shown reproductive toxicity. Special risks are associated with thyroid disorders in pregnant women. Untreated hypothyroidism in pregnant women increases miscarriage risk and foetal effects (e.g. mental retardation, dwarfism). Pregnant women with Graves' disease may transfer thyroid stimulating hormone receptor antibodies to foetus so may cause transient neonatal Graves' disease. Discontinue breastfeeding during LEMTRADA treatment and for 4 months following that course. Benefits of breastfeeding may outweigh potential risks of LEMTRADA exposure. Animal data have shown effects on fertility in humanised mice however a potential impact on human fertility during the period of exposure is unknown based on the available data. **Interactions:** In a controlled clinical trial, MS patients recently treated with beta interferon and glatiramer acetate, were required to discontinue treatment 28 days before initiating treatment with LEMTRADA.

Adverse reactions: **Very common ($\geq 1/10$):** Upper respiratory tract infection, urinary tract infection, Herpes virus infection, lymphopenia, leukopenia, (including neutropenia), Basedow's disease, hyperthyroidism, hypothyroidism, headache, tachycardia, flushing, nausea, urticaria, rash, pruritus, generalised rash, pyrexia, fatigue, chills. **Common ($\geq 1/100 < 1/10$):** Herpes Zoster infection, lower respiratory tract infections, gastroenteritis, oral candidiasis, vulvovaginal candidiasis, influenza, ear infection, pneumonia, vaginal infection, tooth infection, skin papilloma, lymphadenopathy, immune thrombocytopenic purpura, thrombocytopenia, anaemia, haematocrit decreased, leukocytosis, cytokine release syndrome, hypersensitivity including anaphylaxis, autoimmune thyroiditis, goitre, anti-thyroid antibody positive, insomnia, anxiety, depression, MS relapse, dizziness, hypoaesthesia, paraesthesia, tremor, dysgeusia, migraine, conjunctivitis, endocrine ophthalmopathy, vision blurred, vertigo, bradycardia, palpitations, hypotension, hypertension, dyspnoea, cough, epistaxis, hiccups, oropharyngeal pain, asthma, abdominal pain, vomiting, diarrhoea dyspepsia, stomatitis, aspartate aminotransferase increased, alanine aminotransferase increase, erythema, ecchymosis, alopecia, hyperhidrosis, acne, skin lesion, dermatitis, myalgia, muscle weakness, arthralgia, back pain, pain in extremity, muscle spasms, neck pain, musculoskeletal pain, proteinuria, haematuria, menorrhagia, menstruation irregular, chest discomfort, pain, oedema peripheral, asthenia, influenza-like illness, malaise, infusion site pain, blood creatinine increased, contusion and infusion related reaction. **Uncommon ($\geq 1/1,000 < 1/100$):** Onychomycosis, gingivitis, fungal skin infection, tonsillitis, acute sinusitis, cellulitis, pneumonitis, tuberculosis, cytomegalovirus infection, pancytopenia, haemolytic anaemia, acquired haemophilia A, sarcoidosis, decreased appetite, sensory disturbance, hyperaesthesia, tension headache, autoimmune encephalitis, diplopia, ear pain, atrial fibrillation, throat tightness, throat irritation, constipation, gastro-oesophageal reflux disease, gingival bleeding, dry mouth, dysphagia, gastrointestinal disorder, haematochezia, cholecystitis including acalculous cholecystitis and AAC. Blister, night sweats, swelling face,

eczema, vitiligo, alopecia areata, musculoskeletal stiffness, limb discomfort, nephrolithiasis, ketonuria, nephropathies including anti-GBM disease, cervical dysplasia, amenorrhoea, weight decreased, weight increased, red blood cell count decreased, bacterial test positive, blood glucose increased and mean cell volume increase. **Rare ($\geq 1/10,000 < 1/1,000$):** Haemophagocytic lymphohistiocytosis, thrombotic thrombocytopenic purpura. **Unknown:** Listeriosis/Listeria meningitis, EBV infection (including reactivation), Haemorrhagic stroke, cervicocephalic arterial dissection, myocardial ischaemia, myocardial infarction, Pulmonary alveolar haemorrhage, autoimmune hepatitis, hepatitis (associated with EBV infection) and Adult Onset Still's Disease. **Please refer to the SmPC for full details on adverse reactions. List Price: UK: £7,045 per 12mg vial. IE:** Price on Application. **Legal classification:** POM. **Marketing Authorisation Holder:** Sanofi Belgium, Leonardo Da Vincilaan 19, B-1831 Diegem, Belgium. **MA number:** EU/1/13/869/001. **For more information please contact: UK:** Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK or contact uk-medicalinformation@sanofi.com **IE:** Sanofi, 18 Riverwalk, Citywest Business Campus, Dublin 24 or contact IEmedinfo@sanofi.com. **SmPC Date:** 7 July 2023 **Date of preparation:** July 2023.

Adverse events should be reported.
Reporting forms and information can be found at:

In the UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Adverse events should also be reported to the Sanofi Drug Safety department on Tel: 0800 0902314.
Alternatively, send via email to UK-drugsafety@sanofi.com.

In Ireland: www.hpra.ie; email: medsafety@hpra.ie.
Adverse events should also be reported to Sanofi Ireland Ltd.
Tel: 01 403 5600. Alternatively, send via email to IEPharmacovigilance@sanofi.com